FDA expands essential thrombocythemia care

Phase 3 SURPASS ET data showed higher durable response rates with ropeginterferon alfa-2b-njft than with anagrelide.

1

The FDA approved ropeginterferon alfa-2b-njft (BESREMi) for adults with essential thrombocythemia, marking the first new treatment in nearly 30 years.
2

The approval includes newly diagnosed patients who have not received cytoreductive therapy, expanding treatment options for essential thrombocythemia.
3

The approval was based on data from the global phase 3 SURPASS ET trial, showing higher durable response rates compared to anagrelide.
4

Ropeginterferon alfa-2b-njft is designed to target disease-driving bone marrow cells and reduce platelet counts and disease burden.
5

The prescribing information includes a boxed warning for potentially fatal disorders and contraindications for certain patient histories.

1